Ascendiant Capital Markets Issues Pessimistic Forecast for AIM ImmunoTech (NYSE:AIM) Stock Price

AIM ImmunoTech (NYSE:AIM) had its target price cut by equities research analysts at Ascendiant Capital Markets from $5.00 to $4.50 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Separately, Maxim Group lowered their target price on shares of AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating on the stock in a research report on Tuesday, October 22nd.

AIM ImmunoTech Stock Down 3.5 %

AIM ImmunoTech stock opened at $0.21 on Tuesday. AIM ImmunoTech has a twelve month low of $0.16 and a twelve month high of $0.62. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a market cap of $13.41 million, a PE ratio of -0.46 and a beta of -0.36. The firm’s 50 day moving average price is $0.24 and its two-hundred day moving average price is $0.31.

Institutional Trading of AIM ImmunoTech

An institutional investor recently bought a new position in AIM ImmunoTech stock. Armistice Capital LLC purchased a new position in AIM ImmunoTech Inc. (NYSE:AIM) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned about 7.92% of AIM ImmunoTech at the end of the most recent reporting period. 12.02% of the stock is owned by hedge funds and other institutional investors.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).